PDE7A siRNA (h2): sc-41608



The Power to Question

BACKGROUND

Phosphodiesterases (PDE, also designated cyclic nucleotide phosphodiesterase) are important for the downregulation of the intracellular level of the second messenger cyclic adenosine monophosphate (cAMP) by hydrolyzing cAMP to 5'AMP. Phosphodiesterase type 3 isoforms, PDE3A and 3B, are expressed primarily in cardiovascular tissue and adipose tissue, respectively. PDE3A, is found in myocardium and platelets and PDE3B is found in lymphocytes. The PDE7A1 (HCP1) isozyme and the PDE7A2 proteins, alternate splice products of PDE7A, are highly expressed in skeletal muscle. PDE7B is most highly expressed in pancreas. The PDE family contains proteins that serve tissue-specific roles in regulation of lipolysis, glycogenolysis, myocardial contractility, and smooth muscle relaxation.

REFERENCES

- Bloom, T.J. and Beavo, J.A. 1996. Identification and tissue-specific expression of PDE7 phosphodiesterase splice variants. Proc. Natl. Acad. Sci. USA 93: 14188-14192.
- Sheth, S.B., et al. 1997. Cyclic AMP phosphodiesterases in human lymphocytes. Br. J. Haematol. 99: 784-789.
- Han, P., et al. 1997. Alternative splicing of the high affinity cAMP-specific phosphodiesterase (PDE7A) mRNA in human skeletal muscle and heart. J. Biol. Chem. 272: 16152-16157.
- Fisher, D.A., et al. 1998. Isolation and characterization of PDE8A, a novel human cAMP-specific phosphodiesterase. Biochem. Biophys. Res. Commun. 246: 570-577.
- Gantner, F., et al. 1998. Phosphodiesterase profile of human B lymphocytes from normal and atopic donors and the effects of PDE inhibition on B cell proliferation. Br. J. Pharmacol. 123: 1031-1038.
- Liu, H. and Maurice, D.H. 1998. Expression of cyclic GMP-inhibited phosphodiesterases 3A and 3B (PDE3A and PDE3B) in rat tissues: differential subcellular localization and regulated expression by cyclic AMP. Br. J. Pharmacol. 125: 1501-1510.
- 7. Cheung, P.P., et al. 1998. Partial characterization of the active site human platelet cAMP phosphodiesterase, PDE3A, by site-directed mutagenesis. Arch. Biochem. Biophys. 360: 99-104.

CHROMOSOMAL LOCATION

Genetic locus: PDE7A (human) mapping to 8q13.1.

PRODUCT

PDE7A siRNA (h2) is a pool of 3 target-specific 19-25 nt siRNAs designed to knock down gene expression. Each vial contains 3.3 nmol of lyophilized siRNA, sufficient for a 10 μ M solution once resuspended using protocol below. Suitable for 50-100 transfections. Also see PDE7A shRNA Plasmid (h2): sc-41608-SH and PDE7A shRNA (h2) Lentiviral Particles: sc-41608-V as alternate gene silencing products.

For independent verification of PDE7A (h2) gene silencing results, we also provide the individual siRNA duplex components. Each is available as 3.3 nmol of lyophilized siRNA. These include: sc-41608A, sc-41608B and sc-41608C.

STORAGE AND RESUSPENSION

Store lyophilized siRNA duplex at -20° C with desiccant. Stable for at least one year from the date of shipment. Once resuspended, store at -20° C, avoid contact with RNAses and repeated freeze thaw cycles.

Resuspend lyophilized siRNA duplex in 330 μ l of the RNAse-free water provided. Resuspension of the siRNA duplex in 330 μ l of RNAse-free water makes a 10 μ M solution in a 10 μ M Tris-HCl, pH 8.0, 20 mM NaCl, 1 mM EDTA buffered solution.

APPLICATIONS

PDE7A siRNA (h2) is recommended for the inhibition of PDE7A expression in human cells.

SUPPORT REAGENTS

For optimal siRNA transfection efficiency, Santa Cruz Biotechnology's siRNA Transfection Reagent: sc-29528 (0.3 ml), siRNA Transfection Medium: sc-36868 (20 ml) and siRNA Dilution Buffer: sc-29527 (1.5 ml) are recommended. Control siRNAs or Fluorescein Conjugated Control siRNAs are available as 10 µM in 66 µl. Each contain a scrambled sequence that will not lead to the specific degradation of any known cellular mRNA. Fluorescein Conjugated Control siRNAs include: sc-36869, sc-44239, sc-44240 and sc-44241. Control siRNAs include: sc-37007, sc-44230, sc-44231, sc-44232, sc-44233, sc-44234, sc-44235, sc-44236, sc-44237 and sc-44238.

GENE EXPRESSION MONITORING

PDE7A (B-11): sc-398031 is recommended as a control antibody for monitoring of PDE7A gene expression knockdown by Western Blotting (starting dilution 1:200, dilution range 1:100-1:1000) or immunofluorescence (starting dilution 1:50, dilution range 1:50-1:500).

To ensure optimal results, the following support reagents are recommended: 1) Western Blotting: use m-lgG κ BP-HRP: sc-516102 or m-lgG κ BP-HRP (Cruz Marker): sc-516102-CM (dilution range: 1:1000-1:10000), Cruz MarkerTM Molecular Weight Standards: sc-2035, UltraCruz[®] Blocking Reagent: sc-516214 and Western Blotting Luminol Reagent: sc-2048. 2) Immunofluorescence: use m-lgG κ BP-FITC: sc-516140 or m-lgG κ BP-PE: sc-516141 (dilution range: 1:50-1:200) with UltraCruz[®] Mounting Medium: sc-24941 or UltraCruz[®] Hard-set Mounting Medium: sc-359850.

RT-PCR REAGENTS

Semi-quantitative RT-PCR may be performed to monitor PDE7A gene expression knockdown using RT-PCR Primer: PDE7A (h2)-PR: sc-41608-PR (20 μ l). Annealing temperature for the primers should be 55-60° C and the extension temperature should be 68-72° C.

RESEARCH USE

For research use only, not for use in diagnostic procedures.

PROTOCOLS

See our web site at www.scbt.com for detailed protocols and support products.

Santa Cruz Biotechnology, Inc. 1.800.457.3801 831.457.3801 Fax 831.457.3801 Europe +00800 4573 8000 49 6221 4503 0 www.scbt.com